Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC ANTIBIOTICS FOR HUMAN USE ARE EXEMPT FROM BATCH CERTIFICATION

Executive Summary

OTC ANTIBIOTICS FOR HUMAN USE ARE EXEMPT FROM BATCH CERTIFICATION if they are generally recognized as safe and effective and not misbranded. FDA amended the antibiotic drug regulations to exempt OTC antibiotics in July and the rule became effective Aug. 14. In a July 15 Federal Register notice announcing the final rule, FDA explained that current regulations exempt antibiotic drugs for human use from batch certification only if they are approved under an antibiotic application or an abbreviated antibiotic application. "FDA did not intend to exclude OTC antibiotic drugs that are generally recognized as safe and effective from the exemption from batch certification," the notice states. Therefore, the agency said it proposed in July 1985 to amend the antibiotic drug regulations to exempt from batch certification OTC antibiotics that meet the conditions for GRAS/E status and conditions in an applicable final OTC antibiotic drug monograph. FDA noted that it did not receive any comments or requests for an informal conference in response to the proposal.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel